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Abstract
Changing landscape of epilepsy genetic testing gives vast opportunities to both patients 
and clinicians. Significance of precise genetic diagnosis in patients affected by epilepsy 
cannot be overestimated: it not only gives the opportunities of personalized therapeuti-
cal approaches but is also associated with multiple additional benefits for patients, their 
families, and society. Although the burden of Mendelian and chromosomal diseases 
amenable to current diagnostic testing measures is unknown, recently, we have com-
prised a database of more than 880 human genes associated with monogenic diseases 
involving epilepsy or seizures, EpiGene database (http://www.kimg.eu/en/tools/epi-
gene-database). Besides, more than 50 chromosomal syndromes are related to epilepsy 
or seizures. Currently, there are no recommendations or guidelines for genetic testing 
in epilepsy patients addressing specificities of next-generation sequencing technolo-
gies. However, as every genetic testing modality has its own characteristics of specific-
ity/sensitivity, range of clinical indications, and possible bioethical and psychosocial 
implications, genetic testing in epilepsies must be properly selected and applied along 
with proper clinical genetics/genetic counseling services. In this chapter, an overview 
of genetic testing modalities and workflows taking into account genetic architecture 
of epilepsies is given, and practical aspects of genetic testing in epilepsies, including 
advantages/limitations and clinical utility of tests, are discussed.
Keywords: algorithm, diagnostic yield, clinical utility, next-generation sequencing, exome, 
molecular karyotyping
1. Introduction
Recent genetic revolution due to advancements in genomic testing technologies evolves 
into fundamental changes in clinical practice of not only clinical genetics but also other 
medical specialties. Changing landscape of epilepsy genetic testing gives vast opportunities 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
to both patients and clinicians, however, not without additional challenges. Although the 
burden of Mendelian and chromosomal diseases, amenable to current diagnostic testing 
measures, among all patients with epilepsy or seizures is currently unknown, significance 
of precise genetic diagnosis in patients affected by epilepsy cannot be overestimated: it not 
only gives the opportunities of personalized therapeutical approaches but is also associ-
ated with multiple additional benefits for patients, their families, and society. However, as 
every genetic testing modality has its own characteristics of specificity/sensitivity, range of 
clinical indications, and possible bioethical and psychosocial implications, genetic  testing 
in epilepsies must be properly selected and applied along with proper clinical genetics/
genetic counseling services. In this chapter, an overview of genetic testing modalities and 
workflows taking into account genetic architecture of epilepsies is given, and practical 
aspects of genetic testing in epilepsies, including advantages/limitations and clinical utility 
of tests, are discussed.
2. Diagnostic testing in epilepsy genetics clinical practice1
2.1. Genetic and clinical heterogeneity of epilepsy
Both traditional and genomic heritability studies unequivocally show the importance of genetic 
factors in epilepsy [1, 2]. Genetic factors play a role in more than half of all  epilepsies [3]. 
Although a part of these epilepsies may not be amenable for genetic testing in current clinical 
practice (e.g., multifactorial or those due to somatic mutations), many monogenic and chro-
mosomal diseases related to epilepsy or seizures may and should be diagnosed. Most of these 
diagnosable diseases belong to a category of rare diseases (in the European Union defined as a 
disease affecting less than 1 in 2000). One of the main factors delaying diagnostics of any rare 
disease is a low index of suspicion [4]. Indeed, for a referral to medical genetic clinic, a neurol-
ogist must raise a possibility of a genetic disorder in a patient with epilepsy or seizures first.
In any human disorder with a substantial genetic background, the choice of genetic testing 
modalities and workflows depends crucially on the genetic and clinical heterogeneity of a 
given disorder. The overall genetic heterogeneity and number of genetic nosologies involv-
ing epilepsy or seizures are largely unknown; however, epilepsy or seizures may be a symp-
tom of many diverse conditions including channelopathies, neurodevelopmental diseases, 
inborn errors of metabolism, and congenital malformation syndromes [5]. Recently, we have 
comprised the most extensive to our knowledge database of more than 880 human genes 
associated with human monogenic diseases involving epilepsy or seizures, EpiGene database 
(http://www.kimg.eu/en/tools/epigene-database). Besides, more than 50 chromosomal syn-
dromes are related to epilepsy or seizures (see Section 2.5). These numbers give important 
insights into the huge genetic heterogeneity of human disorders involving epilepsy or sei-
zures, comparable to that of intellectual disabilities [6].
1Discussions about usefulness of genetic testing in multifactorial epilepsies (including pharmacogenetic testing) go beyond 
the scope of this chapter.
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For many years the prevailing “dogma” was that epilepsy is a channelopathy [7], and the 
first unveiled channelopathy due to mutations in nicotinic acetylcholine receptor gene 
CHRNA4 became one of long-standing prototypes of genetic epilepsies [8]. Multiple 
channelopathies presenting with variable phenotypes are currently known (e.g., epileptic 
encephalopathies (due to mutations in genes HCN1, KCNA2, KCNB1, SCN8A, SLC13A5, 
STXBP1, and SYN1), benign neonatal seizures (genes KCNQ2 and KCNQ3), a spectrum of 
generalized epilepsy plus to Dravet syndrome due to SCN1A gene mutations). One of the 
major targets of current epilepsy genetic research is a group of disorders defined as epilep-
tic encephalopathies; more than 70 genes have been related to this phenotype, explaining 
20–25% of epileptic encephalopathy cases [9]. Relatively, homogenous clinical presentation 
of this epilepsy phenotype may aid in the recruitment of patients for genetic testing in both 
clinical setting and research. Distinct group of inherited epilepsies comprises progressive 
myoclonic epilepsies—an umbrella term for childhood- or adolescence-onset conditions 
characterized by myoclonus and relentlessly progressive neurodegeneration [10], including 
Unverricht-Lundborg, Lafora disease, neuronal ceroid lipofuscinoses, type 1 sialidosis, GM2 
gangliosidosis, Gaucher disease, MERRF, and some other mitochondrial diseases—and 
other progressive myoclonic epilepsies due to mutations in genes ASAH1, CERS1, GOSR2, 
KCNC1, PRICKLE1, PRICKLE2, and SERPINI1. Other epilepsy phenotypes are much more 
heterogeneous. Surprisingly, the most extensive group of monogenic epilepsies is inher-
ited metabolic diseases, encompassing 373 genes (42% of all genes) in EpiGene database 
(discussed more extensively below). The most frequent genetic epilepsy-associated symp-
toms are psychomotor retardation and intellectual disability (419 and 386 EpiGene diseases, 
respectively). Indeed, epilepsy is a frequent comorbidity (20–30% of cases) of syndromic and 
non-syndromic intellectual disabilities and vice versa; 30% of patients with epilepsy have 
intellectual disabilities [11]. Epilepsy or seizure is an accompanying symptom of a vast range 
of inherited neuromuscular and neurologic diseases, sometimes preceding development 
of other neurologic symptoms such as spastic paraplegias (SPG6, SPG11, SPG18, SPG35, 
SPG47, SPG49, SPG50, SPG51, and SPG52), muscular dystrophies (dystroglycanopathies due 
to mutations in genes B4GAT1, DAG1, FKRP, FKTN, GMPPB, ISPD, LARGE, POMGNT1, 
POMK, POMT1, and POMT2, congenital megaconial dystrophy (CHKB), merosin-deficient 
muscular dystrophy (LAMA2)), hereditary ataxias (spastic ataxia 5, ataxia with oculomo-
tor apraxia (APTX), and ataxia-telangiectasia (ATM), spinocerebellar ataxias (SCA) SCA10 
(ATXN10), SCA13 (GRM1), SCA15 (KIAA0226), SCA20 (SNX14), SCA17 (TBP), SCA12 
(WWOX)), demyelinating diseases (e.g., hypomyelinating leukodystrophy due to muta-
tions in genes AIMP1, FAM126A, GJC2, HSPD1, POLR3A, TUBB4A, leukoencephalopathy 
with vanishing white matter, megalencephalic leukoencephalopathy with subcortical cysts 
(HEPACAM, MLC1), adrenoleukodystrophy, metachromatic leukodystrophy, Krabbe dis-
ease); and hereditary dystonias (dentatorubropallidoluysian atrophy, dystonia 24 (ANO3), 
juvenile onset Parkinson disease 19 (DNAJC6), infantile striatonigral degeneration (NUP62)). 
Paving embryonic neurodevelopmental processes, epilepsy or seizures are very frequent 
symptoms in syndromes with malformations of cortical development, including megalen-
cephalies (AKT3, EZH2, FGFR3, and PIK3CA), lissencephalies (ARX, RELN, VLDLR, ACTB, 
ACTG1, DCX, DYNC1H1, KIF2A, LIS1, TUBA1A, TUBB2B, and TUBG1), polymicrogyrias 
(NDE1, WDR62, FH, KIAA1279, NSDHL, OCLN, GPSM2, RAB3GAP1, RAB3GAP2, RAB18, 
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CHD7, and SRPX2), periventricular nodular heterotopia (ARFGEF2) [12], and neurocuta-
neous syndromes (tuberous sclerosis (TSC1 and TSC2), Sturge-Weber syndrome (GNAQ), 
incontinentia pigmenti (IKBKG), neurofibromatosis (NF1 and NF2)). However, epilepsy or 
seizures may also be variably present in multiple other congenital malformation syndromes, 
including not only CNS malformations (e.g., holoprosencephaly spectrum, pontocerebellar 
hypoplasia, and corpus callosum agenesis) but also malformations in any other organ. More 
than 130 congenital malformation syndromes include epilepsy or seizures as phenotypic 
features (http://www.kimg.eu/en/tools/epigene-database). Five hundred thirty-seven (61%) 
of EpiGene disorders are autosomal recessive, 234 (27%) (autosomal dominant) and 79 (9%) 
(X-linked).
It is not credible that any physician would be able to recognize and differentiate about 1000 
genetic nosologies involving epilepsy or seizures, especially so that most of them are very 
rare and/or have just recently been described. Indeed, 228 of 880 EpiGene diseases (26%) are 
ultrarare, described just in several patients or families. Moreover, nonspecific and overlap-
ping symptoms are frequent characteristics of these disorders. For many genetic epilepsies, 
mutations in a single gene may lead to a broad range of possible phenotypes and vice versa; 
patients with different genetic etiologies may have the same phenotype. To complicate matters 
still further, characteristic MRI and/or EEG features are very rare pointers or even supporters 
for a specific genetic etiology [13, 14]. Therefore, in clinical practice, genetic evaluation of a 
patient with epilepsy or seizures is usually not an easy task.
2.2. Genetic diagnostics of epilepsies: from traditional approach
Conventional etiological evaluation of epilepsy patients was complex and traditionally 
included karyotype, molecular karyotyping, and individually tailored serial metabolic and 
molecular genetic tests [5]. Secondary invasive tests such as biopsies and cerebrospinal fluid 
examination, aid in diagnosis in a small percentage of additional cases [15]. The main perfor-
mance characteristic of any genetic testing modality is a diagnostic yield [16]. Clinical utility 
of various modes of genetic testing was recently evaluated in a retrospective analysis of 110 
patients with various epileptic encephalopathies [17]. Genetic causes were identified in 26% 
of these patients by applying biochemical genetic testing, array comparative genome hybrid-
ization (aCGH), single-gene testing, targeted next-generation sequencing (NGS) testing (gene 
panels of 38, 70, or 327 genes), and whole-exome sequencing (WES) in six patients. In two 
patients, diagnosis was made on clinical grounds and not confirmed by genetic testing (1.8%), 
three patients (2.7%) had microdeletions revealed by aCGH, eight patients (7.2%) had inherited 
metabolic disorders (IEM), and targeted NGS testing resulted in diagnosis in 14 cases (12.7%) 
of patients [17]. The whole diagnostic pathway leading to the final diagnosis is not analyzed 
in this publication; however, a comparable pathway in patients with developmental delay/
intellectual disability, many of whom had epilepsy, was described by López-Pisón et al. [18]. 
In a total of 686 cases (69% of all cases) in whom etiological diagnosis was not established had 
8 tests each on average, including 2887 biochemistry tests, 1582 metabolic tests, 516 karyotyp-
ing/subtelomeric deletion tests, and 525 single-gene testing. Indeed, with sequential targeted 
testing, despite considerable efforts to reach the diagnosis, final diagnosis is frequently not 
established leading to a long “diagnostic odyssey” arduous for both patients and healthcare 
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systems. Moreover, in many clinical situations, traditional approach is not only lengthy but 
also costly. In a study by Soden et al. before WES or whole-genome sequencing (WGS), patients 
had an average of 13.3 prior tests for the cost of $19,100 per family (seizures were observed in 
39 of 100 patients in this study) [19]. The entire traditional diagnostic trajectory average cost 
was $16,409 per patient, substantially higher than the $3972 trio-WES cost, in 17 patients inves-
tigated by Monroe et al. [20]. The first and the only to date prospective comparison of cost-
effectiveness of clinical whole-exome sequencing with a usual testing shows even more cost 
savings: in a cohort of 40 infants with neurodevelopmental disorders and congenital malfor-
mations, standard traditional testing had an average cost per diagnosis of US$21,099 compared 
to US$3937 for singleton WES. The use of WES early in the diagnostic pathway resulted in more 
than three times bigger diagnostic yield, while the price of testing was three times smaller [21]. 
It must be also noted that although Sanger sequencing is frequently entitled as the gold stan-
dard in genetic diagnostic accuracy, there are several recent reports about missed variants. In 
9/105 families diagnosed through WES, the causative variant has not been detected by previous 
Sanger testing of a gene [22]. Finally, all the main professional genetic organizations, includ-
ing the European Society of Human Genetics (ESHG), American College of Medical Genetics 
and Genomics (ACMG), and Canadian College of Medical Geneticists (CCMG), recognize that 
NGS testing may be a more practical approach than traditional gene-by-gene testing in certain 
clinical situations [23–25].
Nevertheless, traditional approach of genetic diagnostics with thorough phenotyping fol-
lowed by targeted genetic testing can still be of value even in the era of NGS testing. Recently, 
a retrospective data analysis of 500 unselected consecutive patients coming to a university 
medical genetic clinic revealed a diagnostic rate of traditional approach reaching 46%. In this 
study, however, the reason for referral of 31% of diagnosed (14% of all) patients was a sus-
pected specific diagnosis or a family history of a definite or suspected genetic disorder (i.e., 
confirmation or ruling out by a targeted genetic testing was needed only). Importantly, 72% 
of the diagnoses were made during the first visits (presumably, due to a highly suggestive 
phenotype), and further targeted testing resulted in huge expenses [26]. However, in patients 
with early onset epilepsy and developmental delay, standard clinical evaluation suggested 
a diagnosis in only 15% of them (11/71) [27]. Therefore, besides confirmation of the known 
family mutation, targeted testing is most suitable in cases with distinctive clinical features and 
minimal locus heterogeneity, for example, MECP2 gene analysis in a girl with characteristic 
Rett syndrome symptoms and clinical course or 15q11q13 methylation analysis in a patient 
with presumable Angelman syndrome. Targeted testing may also be important in selected 
cases where diagnosis cannot be captured by NGS (see Section 2.6). Otherwise, sequential 
targeted testing is largely inefficient and highly time- and cost-consuming.
2.3. To genomic testing technologies
In contrast, next-generation sequencing (NGS) technologies allow for untargeted testing of 
almost all genomic sequence (whole-genome sequencing (WGS)), almost all coding part of 
the genome (whole-exome sequencing (WES)), or simultaneous testing of a predetermined 
set of genes (gene panels). The most comprehensive testing methods—WGS and WES—
usually allow for the most extensive differential diagnostics; however, extraction of useful 
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information from huge amounts of raw data is time- and resource-consuming. Besides, all 
the bioethical/psychosocial implications pertinent to exhaustive genomic testing technolo-
gies must be addressed properly (see Section 2.7). On the other hand, too restrictive diag-
nostic approach leads to missed diagnoses. In our current era of constant accumulation of 
knowledge in human genomic health and disease and continuous technological advances of 
NGS methods, creation of valid recommendations for diagnostic evaluation of human disor-
ders with a considerable genetic background always lags behind scientific and technological 
achievements and is not an easy task in a constantly changing landscape. Currently, there are 
no recommendations or guidelines for genetic testing in epilepsy patients addressing speci-
ficities of NGS technologies [28].
Although sequencing of the first human genome took 15 years and costs approximately 3 bil-
lion US dollars, the new Illumina HiSeq X Ten System can sequence 40–50 genomes per day 
for approximately 1000 US dollars each [29]. However, amounts of obtained data are over-
whelming. Human genome consists of roughly 3.2 billion bp and contains around 3–4 million 
variants (roughly, 1 out of every 1000 bases) [30]. Certainly, the vast majority of these variants 
are benign, determining personal particularities of any individual. Exome, the coding part of 
genome, comprises 1–2% of the whole-genome sequence (~65 Mb) and contains 30,000–60,000 
variants [30, 31]. Human genomic variation is almost immeasurable: the most extensive to 
date human population exome database ExAC (http://exac.broadinstitute.org), encompassing 
more than 60,000 exomes, contains 7.4 million high-quality variants, a variant in one out of 
every eight bases on average. More than a half of these variants (54%) have been found just in 
one individual each [32].
Besides, extraction of useful information from the huge amounts of WGS/WES data is limited 
due to our limited knowledge about human genes. As of February 2015, of approximately 
~19,000 protein-coding genes predicted to exist in the human genome, variants that cause 
Mendelian phenotypes have been identified in ~2937 (~15.5%), while the genes underlying 
about half of all known Mendelian phenotypes (i.e., 3152) have not yet been discovered, 
despite the fact that ~20% (i.e., 643) have been mapped. Moreover, ~16,063 other genes still 
remain candidates for Mendelian phenotypes [33]. Therefore, the major limiting factor of cur-
rent genomic diagnostics is not data generation, but identification and proper interpretation 
of causative variants in the whole flood of “genomic noise.” Multiple powerful bioinformatic 
approaches and tools are implemented in WGS/WES data mining; however, technologies can-
not totally replace human workload. On the contrary, deep knowledge and extensive skills of 
multiple professionals are on a higher demand than ever in order to enable successful usage 
of the technological advances of NGS.
Nevertheless, hundreds of thousands of exomes and tens of thousands of genomes are already 
sequenced, and projects like 100K Genome Project in UK are well under way [30]. Data on 
diagnostic rates of WGS in epilepsy patients are limited: WGS revealed pathogenic and likely 
pathogenic mutations in all six (100% yield) patients with severe early onset epilepsy who 
had previously were refractory to molecular diagnosis by extensive genetic, biochemical, and 
imaging testing [34]. Other WGS studies mostly include patients with various neurodevel-
opmental phenotypes; however, considerable part of them have epilepsy or seizures: in 119 
children WES resulted in a 33% and WGS achieved a remarkable 73% diagnostic rate, while 
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cumulative rate of both WES and WGS was 45% [19]. WES gave a 27% diagnostic rate (27/100 
patients), while WGS in patients with negative prior WES and aCGH testing resulted in 42% 
diagnostic yield (21/50 patients) [35]. Indeed, WGS is the most comprehensive genomic test-
ing mode, encompassing the most extensive mutational spectrum and bypassing many of 
WES limitations in mutation detection (e.g., reliable identification of deep intronic/regulatory 
sequence variants or tandem repeats, see Section 2.6). In a recent study of 156 cases with vari-
able phenotypes, an estimated ~15% of causal variants identified by clinical WGS would most 
likely have been missed by WES [36]. However, our limited knowledge and a huge interpre-
tative workload currently limit the use of WGS, especially in a clinical setting. In the studies 
mentioned above, the vast majority of data obtained from WGS, especially variants beyond 
the coding part of human genome, did not have any diagnostic value and could not reliably 
be ascribed to either benign or pathogenic [35, 36].
Meanwhile, WES gets more and more applications in the diagnostic evaluation of patients with 
epilepsy or seizures. Recently, a study on WES in 314 consecutive patients with unselected 
epilepsies has shown a diagnostic yield of 38.2% [37]. WES in 10 sporadic cases of infantile 
spasms was diagnosed in 40% [38]. Diagnostic output of WES in neurodevelopmental dis-
orders, including epilepsies, was 41% in a group of 78 pediatric patients (12% of them had 
epilepsy) [39]. In a cohort of 500 unselected patients coming to a university medical genetic 
clinic, diagnostic yield of WES was 30%, while that of patients with epilepsy was 35% [40]. 
The output of WES may also depend on when in a diagnostic process it is used: as a first-tier 
test when a genetically heterogeneous disorder is suspected, as a second-tier after the initial 
set of tests is normal, or at the end of the whole diagnostic odyssey. In a prospective study 
of 80 infants with mostly neurodevelopmental disorders and congenital malformations, first-
tier singleton WES resulted in 57.5% diagnostic yield compared to 13.75% diagnostic yield of 
standard investigations (including gene panel testing) [41].
Despite the well-recognized benefits of WGS/WES approaches, they also carry with them a 
high burden of interpretative workload and an increased possibility of detecting incidental 
findings (see Section 2.6) [42]. According to the current European Society of Human Genetics 
(ESHG) recommendations, it is preferable to use a targeted approach of gene panels first in 
order to avoid unsolicited findings or findings that cannot be interpreted [23]. Indeed, about 
80% of human genes are currently not associated with a disease. In the investigation of disor-
ders with limited genetic and phenotypic heterogeneity, gene panels may outperform WES 
because of better coverage, time- and cost-efficiency, and a focused approach excluding inci-
dental findings [29]. Multiple gene panels exist for the investigation of patients with epilep-
tic encephalopathies, cortical malformations, groups of inborn errors of metabolism, various 
other clinical indications, and undifferentiated epilepsy phenotypes. However, due to a huge 
phenotypic and genetic heterogeneity characteristic of disorders involving epilepsy or sei-
zures, as illustrated by EpiGene database (http://www.kimg.eu/en/tools/epigene-database), 
gene panels may lead to smaller diagnostic yields due to their restrictiveness. Testing of 500 
epileptic encephalopathy patients with a gene panel containing 65 genes gave a diagnostic 
yield of 10% [43], 30 gene or 90 gene panels in 349 patients with treatment-resistant epilepsies 
gave a diagnostic yield of 20.3% [44], a gene panel of 46 genes in 216 patients with various 
epilepsies gave 23% diagnostic yield [45], a gene panel trio-testing of 412 genes in 63 probands 
with variable epilepsies gave 23.8% diagnostic yield [46], and a combined approach of 46 gene 
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panel and targeted exon-level aCGH in 400 patients with early onset epilepsy and develop-
mental delay gave 18% diagnostic yield [27]. Comparisons of gene panel testing studies are 
hindered by a huge phenotypic and gene panel variability in all these studies. Indeed, Genetic 
Testing Registry (http://www.ncbi.nlm.nih.gov/gtr/) database lists more than 60 epilepsy 
gene panels from several to 377 genes in size (as of 09/04/2016), and the most comprehensive 
commercially available epilepsy gene panels include from 100 to more than 400 genes, with a 
proportion of genes associated with epilepsy in animal or association studies only and up to 
4% of included genes currently not related to epilepsy or seizures at all [47]. Moreover, there 
is a high inconsistency in both gene numbers and compositions of gene panels even though 
applied for similar groups of patients with epilepsy. In a clinical setting, selection of the most 
appropriate gene panel in a given patient may be challenging because of overlapping, not-
full-blown, atypical clinical presentations [42]. Finally, gene panels rather quickly become 
outdated because of newly discovered genes [41]. A possible solution to these problems is 
the use of “virtual” gene panels applied to WES data. Such an approach gives a flexibility in 
“virtual” gene panel selection and, in cases of negative findings, further possibilities to even-
tually proceed to a much more untargeted analysis of the whole WES data. Besides, carefully 
selected and applied to WES sequencing data, “virtual” gene panels can act as a supplemen-
tary filtering system aiding in time-efficient and better variant calling in terms of exclusion of 
both false-positive (by filtering out non-epilepsy-related genes) and false-negative (by inclu-
sion of epilepsy-related genes which could be missed in the whole flood of variants) find-
ings. Recently, we have created a web tool for a customized gene panel creation according to 
the phenotype (http://www.kimg.eu/generator). Application of this tool to 405 patients with 
various phenotypes increased diagnostic sensitivity from 25.4 to 29.7% [42] comparing to the 
whole WES data analysis.
2.4. Diagnoses not to miss: treatable inborn errors of metabolism
Metabolic epilepsies represent an unquestionable area of precision medicine where timely 
diagnosis and specific treatments tailored to the inherited metabolic defect may mark-
edly improve both the seizures and associated comorbidities as intellectual disability [48]. 
Regrettably, diagnosis of these and other potentially treatable epilepsy-related diseases is still 
often delayed [49]. The reasons for that may be insufficient testing due to a low index of 
suspicion, phenotypic variability and nonspecificity, complexity and limited availability of 
metabolic testing, and invasiveness of some of the diagnostic methods.
More than 370 inborn errors of metabolism (IEM) can present with epilepsy or seizures, and 
more than 90 of these disorders have disease-specific treatments leading to a much more 
better prognosis, improved control of both seizures and comorbid symptoms, and com-
plete avoidance of antiepileptic drugs if diagnosed timely (Table 1; http://www.kimg.eu/en/
tools/epigene-database). However, traditional diagnostics of IEM may be cumbersome as it 
involves a range of metabolic tests performed in specialized laboratories. Urine and/or plasma 
specimen are mostly used; however, in some IEM characteristic metabolites can mainly or 
only be investigated in cerebrospinal fluid (CSF). Histological and/or biochemical investiga-
tions of biopsies (e.g., skin, conjunctiva, or muscle) can aid in the diagnostics of certain other 
IEM. Selection of tests is usually based on a diagnostic hypothesis and requires specialized 
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Inherited metabolic disease Diagnostic metabolites Gene OMIM 
number
1. Disorders of amino acid and peptide metabolism
1. Glycine encephalopathy (GCE) Hyperglycinemia
Hyperglycinuria
Elevated CSF glycine
Elevated CSF/plasma glycine ratio
AMT
GCSH
GLDC
#605899
#605899
#605899
2. Argininemia Hyperarginemia
Diaminoaciduria (arginuria, lysinuria, cystinuria, ornithinuria)
Orotic aciduria
Pyrimidinuria
Increased CSF amino acids (arginine, ornithine, aspartate, threonine, 
glycine, and methionine)
ARG1 #207800
3. Argininosuccinic aciduria Increased citrulline (P)
Increased glutamine (P)
Argininosuccinic aciduria
Orotic aciduria
ASL #207900
4. Citrullinemia, classic Increased citrulline (P)
Increased glutamine (P)
Decreased arginine (P)
Orotic aciduria
ASS1 #215700
5. 3-Methylglutaconic aciduria, type I 
(MGCA1)
Metabolic acidosis
Increased 3-methylglutaconic acid (U)
Increased hydroxyisovaleric acid (U)
AUH #250950
6. Maple syrup urine disease (MSUD) Increased branched chain amino acids (leucine, isoleucine, valine) (P)
Branched chain ketoaciduria (alpha-keto isocaproate, alpha-keto-beta 
methylisovalerate, alpha-keto isovalerate)
Increased alloisoleucine(P)
Positive urine DNPH screening test
BCKDHA
BCKDHB
DBT
#248600
#248600
#248600
7. Homocystinuria due to cystathionine 
beta-synthase deficiency
Homocystinuria
Methioninuria
CBS #236200
8. Carbamoyl phosphate synthetase I 
deficiency, hyperammonemia due to
Decreased citrulline (P)
Decreased arginine (P)
Decreased orotic acid (U)
CPS1 #237300
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Inherited metabolic disease Diagnostic metabolites Gene OMIM 
number
9. Glutaric acidemia I Glutaric aciduria GCDH #231670
10. Hyperinsulinemic hypoglycemia, 
familial, 6 (HHF6)
Hyperinsulinemic hypoglycemia
Hyperammonemia
GLUD1 #606762
11. 17-Beta-hydroxysteroid dehydrogenase 
X deficiency
Increased 2-methyl-3 hydroxybutyrate (U)
Increased tiglylglycine (U)
HSD17B10 #300438
12. Isovaleric acidemia (IVA) Isovaleric acidemia
Isovaleric aciduria
Isovaleryl glycinuria
IVD #243500
13. Homocystinuria-megaloblastic anemia, 
cblG complementation type (HMAG)
Homocystinuria
Hyperhomocysteinemia
Hypomethioninemia
MTR #250940
14. Homocystinuria-megaloblastic anemia, 
cblE complementation type (HMAE)
Homocystinuria
Hyperhomocysteinemia
Hypomethioninemia
MTRR #236270
15. N-Acetylglutamate synthase deficiency 
(NAGSD)
Increased glutamine (P)
Decreased or absent citrulline (P)
Normal orotic acid (U)
NAGS #237310
16. Ornithine transcarbamylase deficiency, 
hyperammonemia due to
Decreased citrulline (P)
Decreased arginine (P)
Increased glutamine (P)
Increased asparagine (P)
Increased orotic acid (U)
Increased ornithine (P)
OTC #311250
17. Phenylketonuria (PKU) Hyperphenylalaninemia
Phenylpyruvic acidemia
PAH #261600
18. Propionic acidemia Increased propionate
Increased 3-hydroxypropionic acid
Increased 3-methylcitric acid
Hyperglycinemia
Hyperglycinuria
PCCA
PCCB
#606054
#606054
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19. Phosphoglycerate dehydrogenase 
deficiency (PHGDHD)
Decrease serine (fasting) (P)
Decreased serine (C)
Normal-to-decreased glycine (fasting) (P)
Decreased glycine (C)
PHGDH #601815
20. Phosphoserine aminotransferase 
deficiency (PSATD)
Decreased serine (P, C)
Decreased glycine (P, C)
PSAT1 #610992
21. Phosphoserine phosphatase deficiency 
(PSPHD)
Decreased serine (P)
Decreased glycine (P)
PSPH #614023
22. Citrullinemia, type II, adult-onset 
(CTLN2)
Citrullinemia SLC25A13 #603471
23. Hyperornithinemia-hyperammonemia-
homocitrullinuria syndrome
Hyperornithinemia
Hyperammonemia
Homocitrullinuria
SLC25A15 #238970
24. 3-Hydroxy-3-methylglutaryl-CoA lyase 
deficiency (HMGCLD)
Hypoketotic hypoglycemia HMGCL #246450
2. Disorders of carbohydrate metabolism
25. Fructose intolerance (hereditary) Hypoglycemia
Fructosemia
ALDOB #229600
26. Glut1 deficiency syndrome Decreased CSF/plasma glucose ratio SLC2A1 #614847
27. Hyperinsulinemic hypoglycemia, familial, 
1 (HHF1)
Hypoglycemia
Hyperinsulinemia
ABCC8 #256450
28. Hyperinsulinemic hypoglycemia, familial, 
5 (HHF5)
Hypoglycemia, postprandial
Hyperinsulinemia, fasting
Elevated serum insulin-to-C-peptide ratio
INSR #609968
29. Hyperinsulinemic hypoglycemia, familial, 
2 (HHF2)
Hypoglycemia
Hyperinsulinemia
KCNJ11 #601820
3. Disorders of fatty acid and ketone body metabolism
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30. Multiple acyl-CoA dehydrogenase 
deficiency (MADD)
Neonatal acidosis
Hypoglycemia
Glutaric aciduria
Glutaric acidemia
Ethylmalonic aciduria
ETFA
ETFB
ETFDH
#231680
#231680
#231680
31. Neurodegeneration due to cerebral folate 
transport deficiency
Decreased methyltetrahydrofolate (MTHF) (C) FOLR1 #613068
32. 3-Hydroxy-3-methylglutaryl-CoA 
synthase-2 deficiency (HMGCS2D)
Hypoketotic hypoglycemia HMGCS2 #605911
4. Disorders of energy metabolism
33. Coenzyme Q10 deficiency, primary, 4 
(COQ10D4)
Increased lactate (P, C) ADCK3 #612016
34. Coenzyme Q10 deficiency, primary, 1 
(COQ10D1)
Lactic acidosis COQ2 #607426
35. Coenzyme Q10 deficiency, primary, 5 
(COQ10D5)
Lactic acidosis COQ9 #614654
36. Encephalopathy, ethylmalonic (EE) Lactic acidosis
Ethylmalonic aciduria
Methylsuccinic aciduria
Increased C4 and C5 acylcarnitine esters (P)
Increased isobutyryl glycine (U)
Increased 2-methylbutyryl glycine (U)
Increased thiosulfate (U)
ETHE1 #602473
37. Cerebral creatine deficiency syndrome 2 
(CCDS2)
Low creatine (C)
Low creatinine (C)
GAMT #612736
38. Cerebral creatine deficiency syndrome 3 
(CCDS3)
Decreased guanidinoacetate (GAA) (P, U) GATM #612718
39. Pyruvate dehydrogenase E1-alpha 
deficiency (PDHAD)
Lactic acidosis
Increased pyruvate (P, C, U)
Increased lactate (P, C, U)
PDHA1 #312170
40. Pyruvate dehydrogenase E1-beta deficiency 
(PDHBD)
Lactic acidosis PDHB #614111
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41. Pyruvate dehydrogenase E3-binding 
protein deficiency (PDHXD)
Lactic acidosis
Increased pyruvate (P)
Increased alanine (P)
PDHX #245349
42. Coenzyme Q10 deficiency, primary, 3 
(COQ10D3)
Increased lactate (P) PDSS2 #614652
5. Disorders of the metabolism of sterols
43. Cerebrotendinous xanthomatosis (CTX) Increased cholestanol (P)
Increased 7 alpha-hydroxylated bile alcohols (U)
CYP27A1 #213700
44. Smith-Lemli-Opitz syndrome (SLOS) Decreased cholesterol (P)
Increased 7-dehydrocholesterol (P)
DHCR7 #270400
45. Bile acid synthesis defect, congenital, 1 
(CBAS1)
Increased serum bilirubin
Abnormal liver function tests
Decreased serum cholesterol
HSD3B7 #607765
6. Disorders of porphyrin and heme metabolism
46. Porphyria, acute intermittent (AIP) Increased delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) 
during acute attacks (U)
HMBS #176000
47. Porphyria variegata Increased fecal protoporphyrin and coproporphyrin
Increased porphyrins (U)
Increased porphobilinogen (PBG) and delta-aminolevulinic acid (ALA) 
during acute attacks (U)
PPOX #176200
48. Porphyria, acute hepatic Hemolytic anemia
Elevated urinary delta-aminolevulinic acid and porphyrins
ALAD #612740
49. Coproporphyria, hereditary (HCP) Increased coproporphyrin isomer III:I ratio (HCP, feces)
Increased harderoporphyrin excretion (feces, harderoporphyria)
CPOX #121300
7. Disorders of lipid and lipoprotein metabolism
50. Sjogren-Larsson syndrome (SLS) Fatty alcohol: NAD+ oxidoreductase deficiency in leukocytes and 
fibroblasts
ALDH3A2 #270200
8. Congenital disorders of glycosylation and other disorders of protein modification
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51. Congenital disorder of glycosylation, type IIc 
(CDG2C)
Neutrophilia, both basal and during infections
Isoelectric focusing of serum transferrin (type II)
SLC35C1 #266265
10. Lysosomal disorders
52. Aspartylglucosaminuria (AGU) Aspartylglucosaminuria AGA #208400
53. Metachromatic leukodystrophy Increased protein (C)
Increased sulfatide (U)
ARSA #250100
54. Krabbe disease Increased protein (C) GALC #245200
55. Gaucher disease, type III Gaucher cells in bone marrow GBA #231000
56. Fabry disease Bone marrow contains lipid-laden macrophages
Increased globotriaosylceramide (GB3) (P, U)
Increased globotriaosylsphingosine (lyso-GB3) (P)
GLA #301500
57. Mucopolysaccharidosis, type IIID (MPS3D) Heparan sulfate (U) GNS #252940
58. Mucopolysaccharidosis, type IIIC (MPS3C) Heparan sulfate (U) HGSNAT #252930
59. Mucopolysaccharidosis, type II (MPS2) Dermatan and heparan sulfate (U) IDS #309900
60. Mucopolysaccharidosis, type IIIB (MPS3B) Heparan sulfate (U) NAGLU #252920
61. Niemann-Pick disease, type C1 (NPC1) Foam cells on bone marrow biopsy
“Sea-blue” histiocytes
Foam cells in visceral organs and CNS
Foam cells contain polymorphic cytoplasmic inclusions consisting of 
lamellar osmiophilic membranes on electron microscopy
NPC1 #257220
62. Niemann-Pick disease, type C2 (NPC2) Foam cells on bone marrow biopsy
“Sea-blue” histiocytes
Foam cells in visceral organs and CNS
Foam cells contain polymorphic cytoplasmic inclusions consisting of 
lamellar osmiophilic membranes on electron microscopy
NPC2 #607625
63. Mucopolysaccharidosis, type IIIA (MPS3A) Heparan sulfate (U) SGSH #252900
10. Peroxisomal disorders
64. Adrenoleukodystrophy (ALD) Very long-chain fatty acids (P, U, C) ABCD1 #300100
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11. Disorders of neurotransmitter metabolism
65. Succinic semialdehyde dehydrogenase deficiency 
(SSADHD)
Increased 4-hydroxybutyric acid (U, P, C)
Increased gamma-aminobutyric acid (U, P, C)
ALDH5A1 #271980
12. Disorders in the metabolism of vitamins and (nonprotein) cofactors
66. Epilepsy, pyridoxine-dependent (PDE) Increased pipecolic acid (U, P, C)
Increased alpha-aminoadipic semialdehyde (P, U, C)
ALDH7A1 #266100
67. Hypophosphatasia, infantile Phosphoethanolaminuria
Increased inorganic pyrophosphate (P, U)
Decreased alkaline phosphatase (P)
ALPL #241500
68. Biotinidase deficiency Increased beta-hydroxyisovalerate, lactate, beta-methylcrotonylglycine, 
beta-hydroxypropionate, methylcitrate (U)
BTD #253260
69. Hyperphenylalaninemia, BH4-deficient, B (HPABH4B) Hyperphenylalaninemia
Decreased homovanillic acid and 5-hydroxyindoleacetic acid (C)
Decreased neopterin and biopterin (U, C)
GCH1 #233910
70. Holocarboxylase synthetase deficiency Increased beta-hydroxyisovalerate, beta-methylcrotonylglycine, beta-
hydroxypropionate, methylcitrate, lactate, tiglylglycine (U)
Normal serum biotin concentration
HLCS #253270
71. Methylmalonic aciduria and homocystinuria, cblF type Methylmalonic acid (U, P)
Homocystine (P, U)
Cystathionine (P, U)
Decreased adenosylcobalamin
Decreased methylcobalamin
LMBRD1 #277380
72. Methylmalonic aciduria, cblA type Methylmalonic acid (P, U)
Long-chain ketonuria
Hyperglycinemia
Decreased adenosylcobalamin
Normal serum cobalamin (vitamin B12)
MMAA #251100
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73. Methylmalonic aciduria and homocystinuria, cblC type Homocystine (P, U)
Methylmalonic acid (P, U)
Decreased methionine (P)
Cystathionine (P, U)
Decreased adenosylcobalamin
Decreased methylcobalamin
Normal serum cobalamin
MMACHC #277400
74. Methylmalonic aciduria and homocystinuria, cblD type Megaloblastic anemia
Homocystinuria
Homocystinemia
Methylmalonic acid (P, U)
Decreased methionine (P)
Decreased adenosylcobalamin
Decreased methylcobalamin
Normal or mildly reduced serum cobalamin
MMADHC #277410
75. Molybdenum cofactor deficiency Increased xanthine (U)
Increased hypoxanthine (U)
Increased S-sulfocysteine (U)
Increased taurine (U)
MOCS1
MOCS2
#252150
#252160
76. Homocystinuria due to deficiency of N(5,10)-
methylenetetrahydrofolate reductase activity
Low to normal methionine (P)
Homocystinemia
Homocystinuria
MTHFR #236250
77. Pyridoxamine 5-prime-phosphate oxidase deficiency Normal to increased glycine (P)
Normal to increased threonine (P)
Decreased arginine (P)
Increased vanillactic acid (U)
Decreased homovanillic acid (C)
Decreased 5-hydroxyindoleacetic acid (C)
Increased 3-methoxytyrosine (C)
Increased glycine, threonine, taurine, histidine (C)
Decreased arginine (C)
Decreased pyridoxal (C)
Decreased pyridoxal 5-prime-phosphate (C)
PNPO #610090
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78. Hyperphenylalaninemia, BH4-deficient, A (HPABH4A) Hyperphenylalaninemia
Decreased homovanillic acid and 5-hydroxyindoleacetic acid (C)
Increased neopterin (U, C)
PTS #261640
79. Hyperphenylalaninemia, BH4-deficient, C (HPABH4C) Hyperphenylalaninemia
Decreased homovanillic acid and 5-hydroxyindoleacetic acid (C)
Increased biopterin (U, C)
QDPR #261630
80. Salla disease (SD) SLC19A2 #249270
81. Thiamine-responsive megaloblastic anemia syndrome 
(TRMA)
0 SLC19A3 #607483
82. Folate malabsorption, hereditary Megaloblastic anemia, folate-responsive
Decreased folate (P, C)
Decreased methionine (P)
Increased formiminoglutamic acid (U)
SLC46A1 #229050
83. Dystonia, dopa-responsive, due to sepiapterin reductase 
deficiency
Decreased 5-hydroxyindoleacetic acid (C)
Decreased homovanillic acid (C)
Increased sepiapterin (C)
Increased biopterin (C)
Increased dihydrobiopterin (C)
Decreased HVA, 5-HIAA, and vanillylmandelic acid (U)
Normal urinary pterins
No hyperphenylalaninemia
SPR #612716
13. Disorders in the metabolism of trace elements and metals
84. Menkes disease Decreased copper and ceruloplasmin (P) ATP7A #309400
85. Wilson disease Decreased ceruloplasmin (P)
Increased copper (U)
ATP7B #277900
Table 1. Treatable inborn errors of metabolism (IEM) associated with epilepsy or seizures.
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knowledge in IEM. Unfortunately, characteristics of seizure semiology, EEG, or head mag-
netic resonance imaging/spectroscopy (MRI/MRS) can only seldom guide differential diag-
nostics of these IEM [13, 48, 50–52]. Besides, there is a huge phenotypic diversity: epilepsy or 
seizures are usually accompanied by other signs and symptoms; multisystem involvement 
is common. Seizures can be the main and the first symptom (e.g., in pyridoxine-dependent 
epilepsy) or a late presentation (e.g., in some of lysosomal storage diseases). Intermediary 
metabolism defects can present with symptomatic seizures during acute crises only [48, 53]. 
Consequently, diagnostics of IEM is sophisticated, time-consuming, and sometimes invasive 
and requires a high degree of specialization, experience, and investments into the diagnostic 
laboratory equipment and human resources (Table 1).
Molecular genetic tests are usually performed for the confirmation of IEM diagnosis and/
or genetic counseling purposes [52]. However, recent emergence of NGS technologies pro-
vides us entirely new diagnostic possibilities. Indeed, previously unsuspected IEM were fre-
quently diagnosed in patients with epilepsy through NGS studies [19, 54], and, vice versa, 
other genetic diseases were diagnosed in patients with suspected IEM [55]. Noninvasiveness 
is a further advantage of NGS tests. Therefore, NGS testing might be considered as a primary 
test and as the most comprehensive screening test for these IEM.
Many IEM present with acute symptoms and metabolic testing in this setting can give the only 
opportunity for timely diagnosis. However, with ever progressing technological advance-
ments, application of NGS methods can be comparably time-efficient and gives very high 
diagnostic yield rates. In a study by Soden et al. [19], accelerated whole-genome sequencing 
has been performed in 15 acutely ill patients in 50 hours (7 of them presented with seizures) 
with a remarkable diagnostic rate of 73%, while turnaround times of whole-exome sequenc-
ing (applied mostly for outpatients) were on average of 16 days. About 20% of all diagnosed 
patients (9 patients of 45 diagnosed) were diagnosed with IEM [19].
2.5. Chromosomal disorders with epilepsy or seizures
Several hundreds of chromosomal disorders are associated with epilepsy or seizures including 
aneuploidies (e.g., ~10% of Down syndrome patients have epilepsy), chromosomal rearrange-
ments (e.g., balanced translocations and disrupting known epilepsy-associated genes), and 
structural variants (syndromic and non-syndromic deletions, duplications, and inversions) 
[56]. In most of these disorders, epilepsy or seizure is a variable feature, and most of these chro-
mosomal disorders are associated with developmental delay/intellectual disability (DD/ID), 
autism, and/or congenital malformations (CM). Historically, G-banding karyotype was used 
for the detection of aneuploidies and large-scale chromosomal rearrangements with an aver-
age diagnostic yield in patients with DD/ID and/or CM not exceeding 3% (excluding Down 
syndrome; [57]). Fluorescent in situ hybridization (FISH) technique was mostly used for the 
diagnosis of known, recognizable microdeletion and microduplication syndromes (e.g., 4pdel 
(Wolf-Hirschhorn), 17pdel (Miller-Dieker), 15q11q13del maternal (Angelman), and 18qdel 
(de Grouchy), all including seizures), and subtelomeric FISH/subtelomeric MLPA allowed for 
identification of subtelomeric gains or losses with additional ~3–6% of diagnoses [58, 59]. The 
major breakthroughs came with the advent of microarrays that have evolved from rather crude 
Seizures50
bacterial artificial chromosome (BAC)-based platforms to the contemporary platforms allow-
ing copy number variation (CNV) analysis down to an exon level. These methods increased 
diagnostic rates in patients with ID/DD and/or CM by ~15% [60] and allowed for elucidation 
of multiple other microdeletion/microduplication syndromes associated with epilepsy or sei-
zures (Table 2). Besides, NGS approaches for CNV variant calling (e.g., by using depth-of-
coverage analysis-based tool CoNIFER [61] have been developed. Importantly, these methods 
are restricted to unbalanced chromosomal rearrangements solely; therefore, they do not abol-
ish completely the need for karyotyping. For example, a small part of patients with ring 14 
1q21.1del/dup 14q23.3del
1q31.3q41dup 15q11.2del
1q41q42.12del 15q13.2q13.3del
1q43q44del 15q13.3del
2q23.1del/dup 15q26.1del
2q23.3q24.2del 15q26.3del
2q24.1del 16p11.2del/dup
2q24dup 16p13.11del
2q24.3del/dup 16p12del
3p25.3del 16p11.2dup
5p15.31p15.2del 16q22.1del/dup
5q11.2del 17p13.3del
5q14.3q15del 17p13.1del
6q22.1del 17p11.2del
6q25.3q27del 17q11.2del/dup
6q26q27del 17q21.31del/dup
7q11.23q21.12del 19p13.2del
7q11.23dup 20p13del
7q22.2q22.3del 20q13.33del
8p23.3p23.1del 21q22del
8q22.2del 22q11.2del
9p24.1del Xp22.33del
9q22.3del Xp11.4dup
9q34.3del Xq11.11del
14q12q22.1del Xq27q28dup
References: 1. Leu et al. [110]; 2. Nevado et al. [111].
Table 2. Microdeletion and microduplication syndromes, associated with epilepsy or seizures.
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and ring 20 chromosomal syndromes do not have any chromosomal material loss [62, 63]. It 
was estimated that <1% of all diagnoses will be undetected by array-based investigations due 
to balanced chromosomal rearrangements [64]. Moreover, different ranges of CNV size are 
typically captured by array-based and NGS-based methods. Although WGS may capture the 
whole spectrum of CNVs (and other structural variations), costs and large amounts of data 
requiring analysis and interpretation currently limits its use [65, 66].
Currently, copy number variation is defined as a genomic segment of at least 50 bp that differs 
in copy number based on two or more genome comparisons (the smaller elements are known as 
insertions or deletions, indels) [65]. Copy number variation of human genome is even more exten-
sive than single-nucleotide variation (a median of 8.9 Mb of sequence is affected by structural 
variants in comparison to 3.6 Mb of single-nucleotide polymorphisms [67]). As of 2014, the most 
extensive general population of CNV database of genomic variants (DGV) contains more than 
2.3 million variants [68], and the bulk of structural variations identified in population controls are 
low-frequency variants (e.g., 65% of variants detected in 2504 individuals had VAF <0.2% [67]). 
Together with a limited knowledge on human pathological copy number variation and func-
tional importance of these genome elements, it creates huge challenges in CNV data interpreta-
tion [69, 70]. Although the American College of Medical Genetics and Genomics provides some 
guidelines in CNV analysis [70], interpretation and reporting, multiple various workflows, and 
strategies exist [60, 69, 71], and diagnostic outputs may substantially differ even in the same cohort 
of patients investigated by the same professionals over just several years [72]. Currently, the 
most extensively investigated are heterozygous de novo or inherited dominant CNVs. However, 
autosomal recessive, imprinting, and X-linked disorders (as much as 10% of all identified caus-
ative CNVs in ID were X-linked in a study by Hehir-Kwa et al.) may also be uncovered [69, 73]. 
Although the pathogenic potential of 1–500 kb small CNVs has not been well elucidated and may 
not be reported in some laboratories performing aCGH (2010 consensus statement on diagnostic 
chromosomal microarray testing recommends a resolution of ≥400 kb as a balance of analytical 
and clinical sensitivity), small CNVs may account for a neurodevelopmental disease phenotype 
in at least 2% of patients, and this range of CNVs is of increasing importance due to spreading 
NGS-based CNV calling methods [74]. Although noncoding copy number variation is usually 
discarded as nonrelevant or uninterpretable, intergenic or intronic structural variation may affect 
gene regulation through position effect and disturbance of regulatory sequences or normal chro-
matin folding [75]. Moreover, somatically acquired structural variation may also play a role [76].
Since 2009, importance of CNVs in various epilepsy phenotypes has been shown in mul-
tiple studies. The biggest diagnostic yields have been achieved in patients with epilepsy 
and various brain malformations: pathogenic and likely pathogenic CNVs had 23.7% of 76 
patients [77] and 22.5% of 169 patients [78]. Microarray testing has been informative in 3.4–8% 
of patients with epileptic encephalopathy [79, 80], 10.9% in 247 cases with epilepsy and associ-
ated ID/DD and/or CM [81], and 5% in 805 patients with unselected epilepsy phenotypes [82]. 
Both recurrent CNVs at 15q13.3, 15q11.2, 16p11.2, and 16p13.11 and rare CNVs may play a 
significant role as one of the major risk factors for common epilepsies, including genetic gen-
eralized epilepsy [83, 84], absence epilepsies [85, 86], and Rolandic epilepsy [87]; however, 
lack of knowledge on the whole phenotypic expression and penetrance of these CNVs present 
considerable challenges for genetic counseling.
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2.6. Next-generation sequencing testing in epilepsies: current problems and limitations
There are two main groups of limitations and problems that must be taken into consideration 
while applying NGS technologies in a diagnostic testing: technological problems/limitations 
and psychosocial/bioethical implications (discussed in Section 2.7).
Although WGS interrogates almost the whole genome and WES—a coding part of the 
genome—diagnostic rate of WGS in patients with epilepsy and other phenotypically and 
genetically diverse neurodevelopmental disorders is seldom above 70%, while the rate of 
WES usually does not exceed 50%. Some types of mutations are reluctant to WGS (e.g., epi-
genetic mutations, structural chromosome rearrangements, tissue-restricted somatic mosa-
icism). Although our knowledge of WGS-reluctant human molecular pathology is very 
limited, there are several recent examples of such pathology discovered in patients with epi-
lepsy. Postzygotic tissue-restricted somatic de novo mutations in AKT3, MTOR, and PIK3CA 
have been identified as the cause of cortical malformation syndromes associated with severe 
epilepsy [88], and somatic mutations in DCX, LIS1, FLNA, and TUBB2B genes as the cause of 
double cortex syndrome, periventricular nodular heterotopia, and pachygyria [89]. Recently 
found biallelic mutations in the box C/D snoRNA U8 gene SNORD118 as a cause of the cere-
bral microangiopathy leukoencephalopathy with calcifications and cysts are an example 
of a pathogenic genomic variation, not amenable to current WES variant filtering practices 
restricted to coding regions and canonical splice sites [90].
Deep intronic, intergenic, regulatory sequence variants (noncoding parts of genome), tandem 
repeats, mtDNA variants, CNVs, variants in GC-rich, repetitive, and homologous regions of 
exome may not be detected in WES [91]. However, at least some of the technological limitations 
of WES technologies may be solved. Capturing of mtDNA variation (e.g., by using MitoSeek 
tool; [92]) and CNV variant calling (see Section 2.5) may be incorporated into the method and 
WES data analysis pipeline. Although detection of very large or small (one to two exons) dele-
tions may be limited, sensitivity of identifying CNVs containing three or more exons has been 
estimated to be 76%, with a specificity of 94% [61]. As both CNVs and mtDNA variations [93] 
play a substantial role in the etiology of genetic epilepsies, these amendments are crucially 
important in this patient group. Unequal coverage of exome leading to missed variants (mostly 
in GC-rich, repetitive, and homologous regions) is a well-known problem [31, 91]. Therefore, 
when testing a limited number of genes in disorders with a limited genetic heterogeneity 
(~50–300 genes comprising about 0.5–2 Mb), gene panels, possibly supplemented with Sanger 
sequencing for poorly covered sequences, may be a better approach [29]. However, as it was 
recently shown in a retrospective study, 99.7% (1491/1533) of variants detected in gene panel 
testing had sufficient coverage for detection in WES [94]. Therefore, for disorders with exten-
sive genetic and phenotypic heterogeneity, the minimal false-negative rate due to unequal 
coverage may be outweighed by a substantially larger diagnostic yield of WES due to a com-
prehensive nature of this technology. Sanger sequencing of potentially causative variants is 
also currently used for the confirmation of NGS testing. However, as it was shown by several 
groups, high-quality (≥500 Q) NGS variants do not require Sanger confirmation and restriction 
of Sanger confirmation to low-quality single-nucleotide variants, and all insertions/deletions 
<10 bp may reduce Sanger confirmation workload by 70–80% and enable cost savings [95].
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Finally, the biggest part of false negatives in WES may be accounted for current variant filtra-
tion, annotation, and interpretation practices; therefore, rate of false negatives have a potential 
to diminish with accumulating information and bioinformatic/technological improvements 
[96, 97]. Although too stringent criteria can lead to false negatives, most likely they are 
unavoidable in a current setting of clinical practice. False-positive diagnoses can potentially 
have more devastating consequences for the family (e.g., through erroneous application of 
prenatal testing); therefore, all doubtful variants are usually ascribed to variants of unknown 
significance (VUS): it is easier to specify earlier suspected diagnosis than to refute previously 
established diagnosis [24].
There are some other non-laboratory-dependent problems potentially leading to missed or mis-
interpreted variants. One of the major steps in variant annotation process is assessing variant 
frequency in the general population. However, population databases cannot be assumed as 
containing data of healthy people only [24]. Besides, the prevalence of reported severe disease-
causing variants in population controls points of the fact that incomplete penetrance and wider 
than appreciated expressivity are more inherent to genetic pathology than usually appreciated. 
One more problem potentially leading to a wrongful diagnosis is an erroneous annotation of vari-
ants and genes in databases and published data. Recently, several genes including CACNA1H, 
SCN9A, EFHC1, CLCN2, GABRD, and SPRX2, at first ascribed to various monogenic forms of 
epilepsy, have later been refuted as causative [9]. Finally, lots of very rare pathogenic variants are 
currently hiding in “private” databases of various laboratories. As both normal and pathogenic 
variation of human genome is almost endless (see Section 2.3), very large collaborative efforts for 
sharing both phenotypic and genotypic data of patients must be employed for the elucidation 
of these ultrarare variants and for ascribing them to certain phenotypes. Recently, the Epilepsy 
Genetics Initiative has created a database to house the clinically sequenced exomes (and, in due 
course, sequenced genomes) and phenotypic data of individuals with epilepsy; one unique pur-
pose of which is to allow ongoing iterative reassessment of unsolved cases [49].
2.7. Building new healthcare practices in a responsible way
Incidental findings are not a new issue in clinical practice, for example, unanticipated findings 
in radiological imaging or even surgery, sometimes leading to dramatic changes in patient care, 
are well-known examples. However, all-inclusive nature of genomic testing, especially WES 
and WGS, means that the generation of a certain amount of unanticipated or incidental findings 
is unavoidable, currently confronted in 1–8% of all tested individuals [98]. Incidental findings 
in genetic testing have several definitions including more general “unexpected positive find-
ings” [98] and deliberate search for pathogenic variants not related to the primary diagnostic 
question [99]. Some of these findings are “actionable,” that is, measures may be implemented 
for preventing/alleviating the consequences of imminent genetic disorder. In other cases, no 
such measures exist. In any case, many psychosocial/bioethical issues may arise; therefore, all 
the main professional genetic organizations, including ESHG, ACMG, and CCMG, provide 
perspectives on how to handle unsolicited/incidental/secondary findings [23, 25, 98, 100].
Uncertainty of medical information, including pathogenicity assessments of laboratory or 
instrumental investigation results and prognostication, is also not a new issue in medicine. In 
genomic testing, a significant number of variants of unknown clinical significance (VUS) that 
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cannot reliably be ascribed to either benign or pathogenic are generated. It is presumable that 
over time due to accumulating knowledge of benign and pathogenic human genome varia-
tion a considerable proportion of these VUS will receive their proper meaning. However, as 
a normal mutation rate will continue to generate a nearly infinite spectrum of variants, the 
challenge of VUS is going to persist; therefore, in clinical genetic practice, professionals must 
prepare their patients for the possibility of uncertainty due to VUS [23].
2.8. Clinical utility of genetic and genomic testing in epilepsies
Establishment of exact etiological diagnosis, where it is possible, is a standard of care in nowa-
days clinical practice. Precise genetic diagnosis has a huge impact on the individuals tested, 
their families, and community, as it allows timely medical interventions, informed reproduc-
tive choices, and avoidance of additional testing. In some cases it enables avoidance of inappro-
priate or detrimental treatments as illustrated by epilepsy due to POLG1 gene mutations where 
valproates are contraindicated due to a threat of fatal hepatic failure [101]. Precise diagnosis can 
also determine the eligibility for clinical trials or enable engagement into appropriate patient 
support groups [102]. Psychosocial benefits of ending the diagnostic odyssey may also be sub-
stantial [103]. Finally, accurate prognostic information can be used by families for obtaining 
appropriate social and educational services and making personal and financial plans.
Undoubtedly, the most important benefits that may be enabled by exact genetic diagnosis are 
disease course-changing specific treatments. With timely diagnosis, there is an opportunity 
to provide life-saving and disability-preventing specific treatments to some epilepsy patients. 
Specific therapies have been initiated or adjusted in 6–8% of diagnosed patients in some stud-
ies [19, 22]. A significant group of treatable metabolic epilepsies provide one of the most veri-
table examples of precision medicine applications (see Section 2.4). Recent examples of specific 
treatments also include individuals with KCNT1 mutations treated with quinidine, children 
with KCNQ2 mutations treated with ezogabine (retigabine), individuals with GRIN2A muta-
tions treated with memantine, and patients with mTORopathies treated with everolimus [49]. 
Fueled by novel epilepsy of genetic discoveries leading to further elucidation of pathogenetic 
disease mechanisms, the list of precision medicine applications in monogenic epilepsies will 
likely expand in the future. However, the first prerequisite to specific treatment applications 
in all these cases is an exact genetic diagnosis. Moreover, as currently up to one-third of all 
epilepsy cases are refractory to current treatments, new discoveries in monogenic forms of 
epilepsy may also fuel research and novel treatment target discoveries in common epilepsies.
In reaching diagnosis, comprehensiveness and untargeted approach of NGS technologies, 
especially WES, may be of special importance. It allows for elucidation of diagnoses in atypi-
cal, unusual, and not-full-blown (e.g., in young patients) phenotypes where phenotype-driven 
diagnostic hypothesis and targeted testing are impossible [19, 104]. Indeed, compatibility of 
a phenotype to that described in literature (the “first case bias”) is one of the main factors in 
diagnostic hypothesis both raising and ascribing of pathogenicity to a novel variant. However, 
as of February 2015, 706 genes or ~24% of all genes associated with a Mendelian phenotype 
in OMIM database were responsible for at least two “clinically discrete” phenotypes [33]. 
Comprehensiveness of WES is also important for diagnostics of more than one genetic disease 
in a patient; such cases comprised four of 105 diagnosed patients in a study by Sawyer et al. [22] 
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and 4.6% of patients in a study by Yang et al. [105]. NGS testing may be the only opportunity 
for diagnosis in life-limiting disorders or in postmortem setting when DNA samples can be 
limited [41]. Finally, novel disease genes are also not an unusual finding in a clinical practice 
with WES or WGS testing and were found in 3.3–8.1% of patients in various studies [37, 40, 
102, 104] and 23% of patients in FORGE study [22]. Importantly, each successful discovery 
opens horizons for diagnostic, preventive, and therapeutic opportunities for the corresponding 
disease [33]. The most common reasons for patients not to receive a diagnosis prior to WES in 
FORGE study were a significant genetic heterogeneity of the interrogated disorder, atypical 
presentation, missed diagnosis by other methods, and novel and ultrarare disorders [22].
2.9. The role of a clinical geneticist
Given all the complexities of genetic diseases’ clinical presentation and phenotype evaluation, 
choice of the right genetic testing strategies, interpretation of genetic testing results and their 
communication to patients and families, genetic counseling regarding further risks and pos-
sibilities for prenatal diagnostics, and finally, sensitive and respectful consideration of all the 
psychosocial/bioethical aspects related to genetic diseases and genetic/genomic testing, the 
role of a clinical geneticist in the whole pathway of genetic diagnostics of a patient with epi-
lepsy or seizures is undisputed. In the contemporary clinical genetic practice, geneticists must 
possess not only proper clinical skills but also abilities to use a vast range of bioinformatic 
tools and databases and have a deep knowledge of not only clinical genetics but also multiple 
genetic and genomic testing specificities.
Success of both targeted genetic testing and untargeted NGS approach is crucially dependent 
on the completeness and accuracy of phenotype evaluation [24, 26, 106]. Given the vast phe-
notypic variability of human monogenic and chromosomal disorders involving epilepsy or 
seizures, illustrated by EpiGene database (http://www.kimg.eu/en/tools/epigene-database), 
phenotyping of patient may include not only neurological examinations and tests but also 
thorough assessment of dysmorphic features, cutaneous signs, congenital malformations, 
variable symptoms of any other organ or organ system impairment, results of prior labora-
tory/radiological and other testings, information on cognitive functioning, etc. Family history/
genealogy data may be helpful. Contrary to expectations of some people, with the advent 
of NGS testing, importance of thorough phenotyping did not diminish [106]. On the con-
trary, the final stages of variant annotation (gene level) and accurate variant interpretation 
are crucially dependent on the full phenotypic picture of a patient. Besides, as in many cases, 
phenotype-driven diagnostic hypothesis is not raised; a constant contact between laboratory 
and clinics with possibilities to perform a “reverse phenotyping” or “genotype to phenotype” 
correlation of identified variants is very important. Indeed, diagnostic yields were lower 
in studies where exome sequencing and interpretation of results were done in laboratories 
separate from clinical units (e.g., gene panel of 447 genes in 148 patients with a suspicion of 
mitochondrial diseases gave a diagnostic yield of only 9.4% in a separate laboratory [107] in 
comparison to 39% yield in a group of 109 patients tested with a gene panel of 238 genes in 
a laboratory connected to clinical unit [55]). In a recently published study, discordance rate 
in the initial interpretation of causal variants between laboratory and clinical geneticists was 
approximately 10% [108]. Finally, standardization and automation of phenotyping may be 
facilitated by tools like PhenoTips [109].
Seizures56
3. Diagnostic testing in epilepsy genetic clinical practice: proposed 
workflow
Currently, there are no recommendations or guidelines for genetic testing in epilepsy patients 
addressing specificities of NGS technologies [28]. We propose a simplified diagnostic work-
flow based on expected diagnostic yields and cost-effectiveness in various clinical situations 
encountered in epilepsy genetic clinical practice (Figure 1). The choice of a diagnostic route 
that is the most appropriate in a given clinical situation requires not only deep knowledge of 
Patient with epilepsy or seizures 
Complex phenotype: 
epilepsy/seizures plus 
 congenital malformations and/or  
neurodevelopmental disorder 
Targeted confirmative testing: 
Sanger sequencing or 
biochemical genetic testing or 
cytogenetic testing (e.g., FISH) 
Isolated epilepsy or 
epilepsy plus neurological/other 
symptoms 
Suggestive phenotype Non-suggestive phenotype 
Targeted confirmative testing 
available and cost-effective 
Established diagnosis 
ArrayCGH 
Untargeted testing (WES) 
Established diagnosis 
Filtration with virtual panel(s) 
Established diagnosis 
Genetic counseling and management 
Analysis of WES 
Yes No
Yes NoNoYes 
Yes No
Figure 1. Provisional diagnostic workflow in patients with epilepsy or seizures.
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a genetic architecture and a molecular pathology of a disorder; multiple technical specificities 
and limitations/disadvantages of diagnostic methods must be taken into consideration.
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